Investor desk
Investors should track partnership announcements and pipeline signals from International Cancer &.
← Back to Events
Tier 1 Global Networking: High ONCOLOGY CONCLUDED
International Cancer & — 2026 — Singapore
CIOC brings together oncology and IO research with tracks on novel therapies, imaging, and policy, positioned at the intersection of basic research and patient care. It attracts Asian clinical and academic networks, valuable for regional trial planning and APAC-focused IO rollout
Presentation data updated Apr 17, 2026, 8:43 PM UTC
Why This Event Matters
CIOC brings together oncology and IO research with tracks on novel therapies, imaging, and policy, positioned at the intersection of basic research and patient care.
Industry impact
CIOC brings together oncology and IO research with tracks on novel therapies, imaging, and policy, positioned at the intersection of basic research and patient care.
Market implications
Expect signals on pricing, formulary strategy, and partnership economics in APAC markets.
Regulatory implications
EMA and national HTA frameworks are frequently debated at industry gatherings.
Investor implications
Investors should track partnership announcements and pipeline signals from International Cancer &.
Competitive implications
Competitive positioning among oncology players is a core theme — compare with prior editions.
Event Significance
Tier-1 industry catalyst
30 /100 composite
International Cancer & is a targeted oncology forum where specialty pipeline readouts and BD conversations drive near-term positioning decisions. Primary driver: speaker calibre and KOL density.
- Speaker quality 14/20
Plenary and late-breaker slots attract global KOLs — high signal for clinical and regulatory teams.
- Company participation 0/20
Smaller exhibitor set — focus on disclosed presenters rather than floor traffic.
- Historical influence 10/20
Some historical catalysts; compare readouts against last cycle.
- Media coverage 6/20
Niche coverage — subscribe for direct abstract alerts.
- Pipeline relevance 0/20
Early science or services-focused — lower near-term PDUFA linkage.
Key Takeaways
Key Themes
oncologyPipeline announcements
Key Markets
Asia-Pacific
Key Opportunities
Partnership dealsLicensing discussionsVendor selection
Timeline & Milestones
- Pre-event intelligence Complete
Abstract discovery in progress; monitor Key Data tab.
- Conference opens Mar 19, 2026 Complete
Live readouts, late-breakers, and partnership announcements.
- Live coverage window Complete
Nova editorial monitors confirmed data releases.
- Conference closes Mar 21, 2026 Complete
Post-event recap, competitive takeaways, and trial updates.
BD teams Investors & analysts Regulatory leaders
Executive Summary
C-level briefCIOC brings together oncology and IO research with tracks on novel therapies, imaging, and policy, positioned at the intersection of basic research and patient care.
Primary audience: BD teams · Investors & analysts · Regulatory leaders
Analyst Watch
Regulatory affairs
EMA and national HTA frameworks are frequently debated at industry gatherings.
Competitive intelligence
Competitive positioning among oncology players is a core theme — compare with prior editions.
Competitive Landscape
Company map →Competitive positioning among oncology players is a core theme — compare with prior editions.
Coverage & Analysis
No coverage articles yet. Check back closer to the event.
Related News & Research
Research hub →Event Intelligence Summary
Standalone summaries for International Cancer & — optimized for research and AI retrieval.
Executive Summary
CIOC brings together oncology and IO research with tracks on novel therapies, imaging, and policy, positioned at the intersection of basic research and patient care.
Analyst View
CIOC brings together oncology and IO research with tracks on novel therapies, imaging, and policy, positioned at the intersection of basic research and patient care.
Investor View
Investors should track partnership announcements and pipeline signals from International Cancer &.
BD View
BD teams should prioritize partnership and licensing conversations at International Cancer &.
Key Facts
- Event
- International Cancer &
- Focus
- oncology
- Region
- Asia-Pacific
- Location
- Singapore
Ask Nova AI
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Frequently Asked Questions
What is International Cancer &?
International Cancer & is a oncology industry conference for executives, clinical leaders, and investors.
Who attends International Cancer &?
Typical attendees include pharma executives, BD teams, investors, and regulatory professionals focused on oncology.
Why is International Cancer & important?
International Cancer & influences partnership timing and policy debates affecting oncology markets for the next 12–18 months.
Where is International Cancer & held?
International Cancer & is held in Singapore.
What should investors watch at International Cancer &?
Track partnership announcements, pipeline readouts, and management commentary on oncology catalysts.
What BD opportunities exist at International Cancer &?
BD teams use International Cancer & for licensing, co-development, and vendor selection across oncology.
How does International Cancer & compare with other pharma conferences?
International Cancer & is a tier-1 global congress for oncology — compare with peer events in the same vertical.
How do I get NovaPharmaNews coverage of International Cancer &?
Subscribe to event alerts on this page for pre-event briefs, live coverage, and post-event analysis.